In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

The biotech's candidate may treat a great number of illnesses that have one thing in common.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $50.71, marking a -2.59% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.04%.

These stocks come with risk, but they also have some exciting long-term growth opportunities.

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

CRISPR Therapeutics (NASDAQ: CRSP) already has notable achievements under its belt. For instance, it developed Casgevy, a medicine for a pair of rare blood diseases, which became the first ...

We'll know more about the company's medium-term prospects by the end of the year.

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...